WALTHAM, Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September:

Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Location: New York, NY

2024 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024
Presentation Time: 3:40 p.m. E.T.
Location: New York, NY

Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Presentation Time: 11:30 a.m. E.T.
Location: Virtual

A webcast of the Cantor and Stifel presentations will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 30 days following the event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.

Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers.

For more information, visit www.Q32Bio.com.

Availability of Other Information About Q32 Bio

Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.